Spots Global Cancer Trial Database for refractory dlbcl
Every month we try and update this database with for refractory dlbcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL | NCT02987400 | Lymphoma, Large... | Venetoclax Obinutuzumab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH |